Nuvation Bio Reports Third Quarter 2022 Financial Results and Provides Business Update

Dosing underway for Phase 1 monotherapy study of NUV-868 in advanced solid tumors

Expect to initiate Phase 1b combination study of NUV-868 by the end of 2022

On track to nominate first clinical candidate from Drug-Drug Conjugate (DDC) platform by the end of 2022

Strong financial position provides cash runway through 2028; cash, cash equivalents and marketable securities of $673.9 million as of September 30, 2022

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported its financial results for the third quarter ended September 30, 2022, and provided a business update.

"We are encouraged by the continued clinical progress of NUV-868 and look forward to the initiation of Phase 1b combination cohorts later this year, which we anticipate will provide better understanding of the potential benefit this therapy can offer a wide range of patients with advanced solid tumors," said David Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio. "We also expect to nominate the first clinical candidate from our DDC platform by the end of 2022, underscoring the growth-driving capabilities of this platform as we work to tackle some of the greatest unmet needs in oncology."

Recent Business Updates

NUV-868, BD2-Selective BETi : Advanced solid tumors

Dosing ongoing in the Phase 1 monotherapy study of NUV-868. Nuvation Bio continues to enroll the Phase 1 monotherapy study in advanced solid tumors. The Company expects to initiate the Phase 1b study of NUV-868 in combination with olaparib in ovarian, pancreatic, metastatic castration-resistant prostate and triple negative breast cancers, or in combination with enzalutamide in metastatic castration-resistant prostate cancer, by the end of 2022.

Drug-Drug Conjugate Platform: Solid tumors

Nomination of first clinical candidate from the DDC platform is expected by the end of 2022.

Third Quarter 2022 Financial Results

As of September 30, 2022, Nuvation Bio had cash, cash equivalents and marketable securities of $673.9 million.

For the three months ended September 30, 2022, research and development expenses were $21.3 million, compared to $17.1 million for the three months ended September 30, 2021. The increase was primarily due to restructuring costs of $1.6 million related to severance and benefit costs and $5.7 million related to contract termination costs offset by $2.8 million decrease in third-party costs related to research services and manufacturing, as well as a $0.3 million decrease in personnel-related costs driven by the termination of the NUV-422 program.

For the three months ended September 30, 2022, general and administrative expenses were $8.0 million, compared to $5.7 million for the three months ended September 30, 2021. The increase was primarily due to a $1.9 million increase in personnel-related costs driven by an increase in headcount and stock-based compensation, a $0.2 million increase in occupancy expenses, a $0.1 million increase in professional fees, and a $0.1 million of restructuring costs related to severance and benefit costs.

For the three months ended September 30, 2022, Nuvation Bio reported a net loss of $27.2 million, or $(0.12) per share. This compares to a net loss of $22.0 million, or $(0.11) per share, for the comparable period in 2021.

About Nuvation Bio

Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio's proprietary portfolio includes mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco. For more information, please visit www.nuvationbio.com .

Forward Looking Statements

Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook" and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the expected timing of clinical trial initiation, the expected timing of clinical candidate nomination from the DDC platform, Nuvation Bio's cash runway and the potential therapeutic benefit of its product candidates. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the management team of Nuvation Bio and are not predictions of actual performance. These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ from those anticipated by the forward-looking statements, including but not limited to the challenges associated with conducting drug discovery and initiating or conducting clinical trials due to, among other things, difficulties or delays in the regulatory process, enrolling subjects or manufacturing or acquiring necessary products; the emergence or worsening of adverse events or other undesirable side effects; risks associated with preliminary and interim data, which may not be representative of more mature data; risks related to cost reduction efforts; and competitive developments. Risks and uncertainties facing Nuvation Bio are described more fully in its Form 10-Q to be filed with the SEC on or about November 3, 2022, under the heading "Risk Factors," and other documents that Nuvation Bio has filed or will file with the SEC. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this press release. Nuvation Bio disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this press release.

Nuvation Bio Inc. and Subsidiaries
Consolidated Balance Sheets
Unaudited
(In thousands, except share and per share data)	September 30,			December 31,
	2022			2021

Assets
Current assets:
Cash and cash equivalents	$	138,690		$	132,423
Prepaid expenses and other current assets		5,094			3,642
Marketable securities		535,255			632,969
Interest receivable on marketable securities		2,350			3,039
Total current assets		681,389			772,073
Property and equipment, net		902			786
Operating lease right-of-use assets		4,060			2,871
Lease security deposit		138			421
Total assets	$	686,489		$	776,151

Liabilities and stockholders' equity
Current liabilities:
Accounts payable	$	2,995		$	3,925
Current operating lease liabilities		1,100			863
Accrued expenses		9,916			12,137
Total current liabilities		14,011			16,925
Warrant liability		1,171			11,037
Non-current operating lease liabilities		3,372			2,192
Total liabilities		18,554			30,154

Stockholders' equity
Class A and Class B common stock and additional paid in capital, $0.0001 par value per share; 1,060,000,000
(Class A 1,000,000,000, Class B 60,000,000) shares authorized as of September 30, 2022 and December 31, 2021,
218,392,607 (Class A 217,392,607, Class B 1,000,000) and 217,948,568 (Class A 216,948,568, Class B 1,000,000)
shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively		922,209			909,985
Accumulated deficit		(246,157	)		(162,803	)
Accumulated other comprehensive income		(8,117	)		(1,185	)
Total stockholders' equity		667,935			745,997
Total liabilities and stockholders' equity	$	686,489		$	776,151

Nuvation Bio Inc. and Subsidiaries

Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except per share data)
	Three Months Ended September 30,						Nine Months Ended September 30,
	2022			2021			2022			2021


Operating expenses:
Research and development	$	21,294		$	17,122		$	70,944		$	47,035
General and administrative		8,044			5,669			24,455			16,674
Total operating expenses		29,338			22,791			95,399			63,709

Loss from operations		(29,338	)		(22,791	)		(95,399	)		(63,709	)

Other income (expense):
Interest income		2,127			847			3,925			2,061
Investment advisory fees		(263	)		(170	)		(647	)		(454	)
Change in fair value of warrant liability		462			125			9,866			332
Realized (loss) gain on marketable securities		(191	)		10			(1,099	)		56
Total other (expense) income, net		2,135			812			12,045			1,995

Loss before income taxes		(27,203	)		(21,979	)		(83,354	)		(61,714	)

Provision for income taxes		-			-			-			-

Net loss	$	(27,203	)	$	(21,979	)	$	(83,354	)	$	(61,714	)
Net loss attributable to common stockholders
Net loss per share attributable to common stockholders, basic and diluted	$	(0.12	)	$	(0.11	)	$	(0.39	)	$	(0.32	)
Weighted average common shares outstanding, basic and diluted		218,300			207,101			216,123			193,730

Comprehensive loss:
Net loss	$	(27,203	)	$	(21,979	)	$	(83,354	)	$	(61,714	)
Other comprehensive income, net of taxes:
Unrealized loss on available-for-sale securities		(1,139	)		(369	)		(6,932	)		(1,169	)

Comprehensive loss	$	(28,342	)	$	(22,348	)	$	(90,286	)	$	(62,883	)

View source version on businesswire.com: https://www.businesswire.com/news/home/20221103005132/en/

Nuvation Bio Investor Contact:
ir@nuvationbio.com

Nuvation Bio Media Contact:
Argot Partners
Leo Vartorella
leo@argotpartners.com

News Provided by Business Wire via QuoteMedia

nanotech investing nyse:nuvb

NUVB

Nuvation Bio Announces Appointment of Dr. Robert Mashal to its Board of Directors

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of Robert Mashal, M.D. to its Board of Directors.

"We are delighted to have Dr. Mashal join our Board of Directors," said David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio. "Robert is a seasoned biotech industry veteran and his experience as an investor, operator, and medical oncologist will provide us with valuable insights. We look forward to working with Robert to advance Nuvation's pipeline."

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Nuvation Bio Announces Formation of Oncology-Focused Scientific Advisory Board

Scientific Advisory Board members bring significant global expertise in oncology drug and clinical development

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the formation of a Scientific Advisory Board. The Scientific Advisory Board will work alongside the Nuvation Bio management team to advance its pipeline of therapeutic candidates for some of the most difficult-to-treat cancers.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Sona Nanotech Grants Options

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that it has granted 25,000 incentive stock options under the Company's Stock Option Plan ("Option Plan") to a consultant. Each option is exercisable into one common share at a price of $0.30 per share and will vest at the rate of 25% every six months. The options will expire five years from the date of grant. All other terms and conditions of the options are in accordance with the terms of the Company's Option Plan.

Contact:
David Regan, CEO
+1-902-536-1932
david@sonanano.com

Keep reading...Show less

Veru to Present at the American Diabetes Association's 84th Scientific Sessions

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that the Company will present two presentations at the American Diabetes Association's 84 th Scientific Sessions, taking place June 21-24, 2024, in Orlando, Florida.

The presentations are:

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor

Dr. Selvaggi was instrumental in the development and approval of lung cancer drugs Zykadia for Novartis and Opdivo for Bristol Myers Squibb
CEL-SCI's Multikine immunotherapy improves the 5-year survival of head and neck cancer patients to 73% compared to 45% in controls and cuts the 5-year risk of death by 50%
FDA has given CEL-SCI the go-ahead to commence a confirmatory Registration Study for Multikine for the target population in head and neck cancer
Dr. Selvaggi will be supporting CEL-SCI to bring Multikine to patients through a confirmatory registrational path that has been agreed with regulatory authorities and that has a potential for cure

CEL-SCI Corporation (NYSE American: CVM) today announced Dr. Giovanni Selvaggi, an oncology key opinion leader instrumental in successfully bringing several drugs to market has joined CEL-SCI as a Clinical Advisor. Dr. Selvaggi joins CEL-SCI as the Company recently received its go-ahead from the U.S. Food and Drug Administration (FDA) for its confirmatory Registration Study of Multikine* in the treatment of head and neck cancer.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240606671425/en/

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Ventyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers

VTX3232 demonstrated improvements in body weight, systemic inflammatory biomarkers and cardiometabolic parameters in diet-induced obesity (DIO) mice

Additive effects were observed for VTX3232 in combination with the GLP-1 receptor agonist semaglutide across key endpoints compared to semaglutide or VTX3232 alone

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less


Nuvation Bio Inc. and Subsidiaries
Consolidated Balance Sheets
Unaudited
(In thousands, except share and per share data)	September 30,			December 31,
	2023			2022

Assets
Current assets:
Cash and cash equivalents	$	24,395		$	101,099
Prepaid expenses and other current assets		2,976			3,819
Marketable securities		594,944			559,915
Interest receivable on marketable securities		3,033			2,485
Total current assets		625,348			667,318
Property and equipment, net		764			894
Operating lease right-of-use assets		4,033			3,791
Lease security deposit		138			138
Other non-current assets		587			—
Total assets	$	630,870		$	672,141

Liabilities and stockholders' equity
Current liabilities:
Accounts payable	$	2,373		$	2,139
Current operating lease liabilities		1,915			1,206
Accrued expenses		11,855			9,816
Total current liabilities		16,143			13,161
Warrant liability		590			850
Non-current operating lease liabilities		2,549			3,054
Total liabilities		19,282			17,065

Stockholders' equity
Class A and Class B common stock and additional paid in capital, $0.0001 par value per share; 1,060,000,000
(Class A 1,000,000,000, Class B 60,000,000) shares authorized as of September 30, 2023 and December 31, 2022,
218,944,053 (Class A 217,944,053, Class B 1,000,000) and 218,632,699 (Class A 217,632,699, Class B 1,000,000)
shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively		943,903			927,604
Accumulated deficit		(329,017	)		(267,002	)
Accumulated other comprehensive income		(3,298	)		(5,526	)
Total stockholders' equity		611,588			655,076
Total liabilities and stockholders' equity	$	630,870		$	672,141

Nuvation Bio Inc. and Subsidiaries
Consolidated Balance Sheets
Unaudited
(In thousands, except share and per share data)	June 30,			December 31,
	2023			2022

Assets
Current assets:
Cash and cash equivalents	$	50,065		$	101,099
Prepaid expenses and other current assets		3,531			3,819
Marketable securities		580,835			559,915
Interest receivable on marketable securities		2,795			2,485
Total current assets		637,226			667,318
Property and equipment, net		804			894
Operating lease right-of-use assets		3,242			3,791
Lease security deposit		138			138
Total assets	$	641,410		$	672,141

Liabilities and stockholders' equity
Current liabilities:
Accounts payable	$	2,577		$	2,139
Current operating lease liabilities		1,283			1,206
Accrued expenses		9,553			9,816
Total current liabilities		13,413			13,161
Warrant liability		972			850
Non-current operating lease liabilities		2,393			3,054
Total liabilities		16,778			17,065

Stockholders' equity
Class A and Class B common stock and additional paid in capital, $0.0001 par value per share; 1,060,000,000
(Class A 1,000,000,000, Class B 60,000,000) shares authorized as of June 30, 2023 and December 31, 2022,
218,899,462 (Class A 217,899,462, Class B 1,000,000) and 218,632,699 (Class A 217,632,699, Class B 1,000,000)
shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively		938,395			927,604
Accumulated deficit		(309,368	)		(267,002	)
Accumulated other comprehensive income		(4,395	)		(5,526	)
Total stockholders' equity		624,632			655,076
Total liabilities and stockholders' equity	$	641,410		$	672,141

Nuvation Bio Inc. and Subsidiaries

Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except per share data)
	Three Months Ended June 30,						Six Months Ended June 30,
	2023			2022			2023			2022

Operating expenses:
Research and development	$	18,590		$	28,922		$	37,377		$	49,650
General and administrative		7,541			8,948			15,275			16,411
Total operating expenses		26,131			37,870			52,652			66,061

Loss from operations		(26,131	)		(37,870	)		(52,652	)		(66,061	)

Other income (expense):
Interest income		6,086			841			11,065			1,798
Investment advisory fees		(231	)		(215	)		(461	)		(384	)
Change in fair value of warrant liability		(265	)		3,080			(123	)		9,404
Realized loss on marketable securities		(99	)		(694	)		(195	)		(908	)
Total other income (expense), net		5,491			3,012			10,286			9,910

Loss before income taxes		(20,640	)		(34,858	)		(42,366	)		(56,151	)

Provision for income taxes		-			-			-			-

Net loss	$	(20,640	)	$	(34,858	)	$	(42,366	)	$	(56,151	)
Net loss attributable to common stockholders
Net loss per share attributable to common stockholders, basic and diluted	$	(0.09	)	$	(0.16	)	$	(0.19	)	$	(0.26	)
Weighted average common shares outstanding, basic and diluted		218,848			216,603			218,795			215,016

Comprehensive loss:
Net loss	$	(20,640	)	$	(34,858	)	$	(42,366	)	$	(56,151	)
Other comprehensive loss, net of taxes:
Unrealized (loss) gain on available-for-sale securities		(1,457	)		(761	)		1,131			(5,793	)

Comprehensive loss	$	(22,097	)	$	(35,619	)	$	(41,235	)	$	(61,944	)

	Date:	Wednesday, June 12, 2024
	Time:	1:45 p.m. ET

Nuvation Bio Reports Third Quarter 2022 Financial Results and Provides Business Update

Nuvation Bio Announces Appointment of Dr. Robert Mashal to its Board of Directors

Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-1511 for the Treatment of Advanced Solid Tumors

Nuvation Bio Reports Third Quarter 2023 Financial Results and Provides Business Update

Nuvation Bio Reports Second Quarter 2023 Financial Results and Provides Business Update

Nuvation Bio Announces Formation of Oncology-Focused Scientific Advisory Board

Sona Nanotech Grants Options

Sona Nanotech

Overview

Longeveron to Present at the Emerging Growth Virtual Conference on June 12, 2024

Veru to Present at the American Diabetes Association's 84th Scientific Sessions

Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor

Ventyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers

Latest News

Latest Press Releases

Noble Announces Filing of NI 43-101 Technical Report for Previously Announced Mann Central and Mann West Initial Resources

Homerun Resources Inc. Appoints Strand Hanson Limited as UK Financial Adviser to Explore Dual Listing on London Stock Exchange

Skyharbour Expands Uranium Exploration Portfolio to Over 616,000 Hectares Across Thirty-Seven Projects in the Athabasca Basin, Northern Saskatchewan

SAGA Metals Completes Strategic Infrastructure Upgrades in Preparation for Major Drill Program at the 100% Owned Radar Titanium Property in Labrador, Canada

Related News

Capricorn Metals' Karlawinda Expansion Gets Thumbs Up

Victory Metals Marks "Breakthrough" Rare Earth Oxide Production at North Stanmore

Noble Announces Filing of NI 43-101 Technical Report for Previously Announced Mann Central and Mann West Initial Resources

Homerun Resources Inc. Appoints Strand Hanson Limited as UK Financial Adviser to Explore Dual Listing on London Stock Exchange

Skyharbour Expands Uranium Exploration Portfolio to Over 616,000 Hectares Across Thirty-Seven Projects in the Athabasca Basin, Northern Saskatchewan

SAGA Metals Completes Strategic Infrastructure Upgrades in Preparation for Major Drill Program at the 100% Owned Radar Titanium Property in Labrador, Canada

LaFleur Minerals Engages Advisors for Strategic Beacon Gold Mill Restart Debt Financing and Announces LIFE and Charity Flow-Through Unit Offerings

TOP STOCKS